Edition:
United States

Profile: Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

1.85USD
4:00pm EDT
Change (% chg)

$-0.02 (-1.07%)
Prev Close
$1.87
Open
$1.85
Day's High
$1.85
Day's Low
$1.81
Volume
10,359
Avg. Vol
31,564
52-wk High
$4.35
52-wk Low
$1.25

Nymox Pharmaceutical Corp, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment.

The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Company Address

Nymox Pharmaceutical Corp

9900 Cavendish Blvd Suite 306
SAINT-LAURENT   QC   H4M 2V2

Company Web Links